RobertsGWHelboeTNielsenCBMGallusASJensenICoshD, Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother2003; 37: 799–803. DOI 10.1345/aph.1A372
HarrisonLJohnstonMMassicottePMCrowtherMMoffatKHirshJ. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med1997; 126: 133–6.
4.
HirshJDalenJEAndersonDRPollerLBusseyHAnsellJ, Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest2001; 119 (suppl): 8S–21S.
5.
MaMKWooMHMcLeodHL. Genetic basis of drug metabolism. Am J Health Syst Pharm2002; 59: 2061–9.
6.
HigashiMKVeenstraDLKondoLMWittkowskyAKSrinouan-prachanhSLFarinFM, Association between CYP2C9 genetic variations and anticoagulation-related outcomes during warfarin therapy. JAMA2002; 287: 1690–8.
7.
KayserSRDangMTHambletonJ. The influence of racial background on warfarin dosage requirement (abstract). Blood2002; 100: 501a.
8.
TakahashiHKashimaTNomizoYMuramotoNShimizuTNasuK, Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther1998; 63: 519–28.
9.
LeeJLeeBKimKAhnHSuhOLeeM, Factors affecting warfarin therapy following cardiac valve surgery. Ann Pharmacother2002; 36: 1845–50. DOI 10.1345/aph.1A431
10.
HawkTLHavrdaDE. Effect of stress on international normalized ratio during warfarin therapy. Ann Pharmacother2002; 36: 617–20. DOI 10.1345/aph.1A263
11.
FennertyADolbenJThomasPBackhouseGBentleyDPCampbellIA, Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ1984; 288: 1268–70.
12.
Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent onset cerebral ischemia. European Atrial Fibrillation Trial Study Group. N Engl J Med1995; 333: 5–10.
13.
Stroke Prevention in Atrial Fibrillation study. Final results. Circulation1991; 84: 527–39.
14.
MohrJPThompsonJLLazarRMLevinBSaccoRLFurieKL, A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med2001; 345: 1444–51.
15.
WHO Expert Committee on Biological Standardization. 33rd report. Technical report series no. 687. Geneva: World Health Organization, 1983: 81.
16.
WhiteRHZhouHRomanoPS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thrombolism. Arch Intern Med1998; 158: 1005–10.
17.
KovacsMJAndersonDAWellsPS. Prospective assessment of a nomogram for the initiation of oral anticoagulation therapy for outpatient treatment venous thromboembolism. Pathophysiol Haemost Thromb2002; 32: 131–3.
18.
KovacsMJWellsPSAndersonDMorrowBFlorackPBurtonE, Randomized prospective comparison of 5mg vs 10mg dosing nomograms for initiation of oral anticoagulation therapy for acute venous thromboembolism (abstract P806). Presented at the XVIII Congress of the International Society on Thrombosis and Haemostatis meeting, July 6-12, 2001.
19.
GedgeJOrmeSHamptonKKChannerKSHendraTJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing2000; 29: 31–4.
20.
PengoVBiasioloAPegoraroC. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol2001; 88: 1214–6.
21.
WhiteRHHongRVenookAPDaschbachMMMurrayWMungallDR, Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J Gen Intern Med1987; 2: 141–8.
22.
MamdaniMMRacineEMcCreadieSZimmermanCO'SullivanTLJensenG, Clinical and economic effectiveness of an inpatient anticoagulation service. Pharmacotherapy1999; 19: 1064–74.
23.
DagerWEBranchJMKingJHWhiteRHQuanRSMusallamNA, Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother2000; 34: 567–72. DOI 10.1345/aph.18192
24.
CannegieterSCRosendaalFRWintzenARvan der MeerFJVandenbrouckeJPBrietE. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med1995; 333: 11–7.
25.
HurlenMAbdelnoorMSmithPErikssenJArnesenH. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med2002; 347: 969–74.
26.
OdenAFahlenM. Oral anticoagulation and risk of death: a medical record linkage study. BMJ2002; 325: 1073–5.
